RARE logo

RARE

Profile

Full Name

Ultragenyx Pharmaceutical Inc.

Ticker Symbol

RARE

Exchange

NASDAQ

Country

United States

IPO

January 31, 2014

Indexes

Not included

Employees

1294

Key Details

Price

$35.20

Last Dividend

-

TTM Dividend Yield

-

Annual Revenue

$560.23M(+29.01% YoY)

Annual EPS

-$6.29(+23.76% YoY)

Next earnings date

May 2, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Oct 22, 24 Cantor Fitzgerald
Overweight
Oct 21, 24 TD Cowen
Buy
Oct 1, 24 Cantor Fitzgerald
Overweight
Sep 26, 24 RBC Capital
Outperform
Sep 20, 24 Cantor Fitzgerald
Overweight
Sep 16, 24 Cantor Fitzgerald
Overweight
Aug 5, 24 Barclays
Overweight
Aug 2, 24 Wells Fargo
Overweight
Aug 2, 24 Wedbush
Neutral
Aug 2, 24 Goldman Sachs
Buy

Institutional Ownership

  • What is the ticker symbol for Ultragenyx Pharmaceutical?
  • Does Ultragenyx Pharmaceutical pay dividends?
  • What sector is Ultragenyx Pharmaceutical in?
  • What industry is Ultragenyx Pharmaceutical in?
  • What country is Ultragenyx Pharmaceutical based in?
  • When did Ultragenyx Pharmaceutical go public?
  • Is Ultragenyx Pharmaceutical in the S&P 500?
  • Is Ultragenyx Pharmaceutical in the NASDAQ 100?
  • Is Ultragenyx Pharmaceutical in the Dow Jones?
  • When was Ultragenyx Pharmaceutical's last earnings report?
  • When does Ultragenyx Pharmaceutical report earnings?
  • Should I buy Ultragenyx Pharmaceutical stock now?

What is the ticker symbol for Ultragenyx Pharmaceutical?

The ticker symbol for Ultragenyx Pharmaceutical is NASDAQ:RARE

Does Ultragenyx Pharmaceutical pay dividends?

No, Ultragenyx Pharmaceutical does not pay dividends

What sector is Ultragenyx Pharmaceutical in?

Ultragenyx Pharmaceutical is in the Healthcare sector

What industry is Ultragenyx Pharmaceutical in?

Ultragenyx Pharmaceutical is in the Biotechnology industry

What country is Ultragenyx Pharmaceutical based in?

Ultragenyx Pharmaceutical is headquartered in United States

When did Ultragenyx Pharmaceutical go public?

Ultragenyx Pharmaceutical's initial public offering (IPO) was on January 31, 2014

Is Ultragenyx Pharmaceutical in the S&P 500?

No, Ultragenyx Pharmaceutical is not included in the S&P 500 index

Is Ultragenyx Pharmaceutical in the NASDAQ 100?

No, Ultragenyx Pharmaceutical is not included in the NASDAQ 100 index

Is Ultragenyx Pharmaceutical in the Dow Jones?

No, Ultragenyx Pharmaceutical is not included in the Dow Jones index

When was Ultragenyx Pharmaceutical's last earnings report?

Ultragenyx Pharmaceutical's most recent earnings report was on Feb 13, 2025

When does Ultragenyx Pharmaceutical report earnings?

The next expected earnings date for Ultragenyx Pharmaceutical is May 2, 2025

Should I buy Ultragenyx Pharmaceutical stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page